These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

499 related items for PubMed ID: 16887442

  • 1. Prediction of resistance to intravenous immunoglobulin treatment in patients with Kawasaki disease.
    Egami K, Muta H, Ishii M, Suda K, Sugahara Y, Iemura M, Matsuishi T.
    J Pediatr; 2006 Aug; 149(2):237-40. PubMed ID: 16887442
    [Abstract] [Full Text] [Related]

  • 2. Analysis of potential risk factors associated with nonresponse to initial intravenous immunoglobulin treatment among Kawasaki disease patients in Japan.
    Uehara R, Belay ED, Maddox RA, Holman RC, Nakamura Y, Yashiro M, Oki I, Ogino H, Schonberger LB, Yanagawa H.
    Pediatr Infect Dis J; 2008 Feb; 27(2):155-60. PubMed ID: 18174868
    [Abstract] [Full Text] [Related]

  • 3. Inflammatory cytokines as predictors of resistance to intravenous immunoglobulin therapy in Kawasaki disease patients.
    Sato S, Kawashima H, Kashiwagi Y, Hoshika A.
    Int J Rheum Dis; 2013 Apr; 16(2):168-72. PubMed ID: 23773640
    [Abstract] [Full Text] [Related]

  • 4. Early treatment with intravenous immunoglobulin in patients with Kawasaki disease.
    Tse SM, Silverman ED, McCrindle BW, Yeung RS.
    J Pediatr; 2002 Apr; 140(4):450-5. PubMed ID: 12006960
    [Abstract] [Full Text] [Related]

  • 5. Treatment of acute Kawasaki disease: aspirin's role in the febrile stage revisited.
    Hsieh KS, Weng KP, Lin CC, Huang TC, Lee CL, Huang SM.
    Pediatrics; 2004 Dec; 114(6):e689-93. PubMed ID: 15545617
    [Abstract] [Full Text] [Related]

  • 6. Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease.
    Kobayashi T, Inoue Y, Takeuchi K, Okada Y, Tamura K, Tomomasa T, Kobayashi T, Morikawa A.
    Circulation; 2006 Jun 06; 113(22):2606-12. PubMed ID: 16735679
    [Abstract] [Full Text] [Related]

  • 7. Immunoglobulin failure and retreatment in Kawasaki disease.
    Durongpisitkul K, Soongswang J, Laohaprasitiporn D, Nana A, Prachuabmoh C, Kangkagate C.
    Pediatr Cardiol; 2003 Jun 06; 24(2):145-8. PubMed ID: 12457253
    [Abstract] [Full Text] [Related]

  • 8. The relationship of eosinophilia to intravenous immunoglobulin treatment failure in Kawasaki disease.
    Kuo HC, Yang KD, Liang CD, Bong CN, Yu HR, Wang L, Wang CL.
    Pediatr Allergy Immunol; 2007 Jun 06; 18(4):354-9. PubMed ID: 17584314
    [Abstract] [Full Text] [Related]

  • 9. Treatment of Kawasaki disease with a moderate dose (1 g/kg) of intravenous immunoglobulin.
    Khowsathit P, Hong-Hgam C, Khositseth A, Wanitkun S.
    J Med Assoc Thai; 2002 Nov 06; 85 Suppl 4():S1121-6. PubMed ID: 12549785
    [Abstract] [Full Text] [Related]

  • 10. Corticosteroids in the initial treatment of Kawasaki disease: report of a randomized trial.
    Sundel RP, Baker AL, Fulton DR, Newburger JW.
    J Pediatr; 2003 Jun 06; 142(6):611-6. PubMed ID: 12838187
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Treatment of Kawasaki disease using locally product intravenous immunoglobulin.
    Sangtawesin C, Kirawitaya T, Layangkool T, Nawasiri W, Vimolsarawong N.
    J Med Assoc Thai; 2003 Aug 06; 86 Suppl 3():S656-60. PubMed ID: 14700163
    [Abstract] [Full Text] [Related]

  • 15. [Effects of three intravenous gamma globulin regimens on Kawasaki disease and relevant coronary complication rates in pediatric patients: a comparative study].
    DU ZD, Zhao D, DU JB, Lu S, Yi JM, Hou AC, Zhou ZS, Ding GF, Beijing Kawasaki Disease Epidemilogy Study Grou.
    Zhonghua Yi Xue Za Zhi; 2007 Nov 27; 87(44):3119-21. PubMed ID: 18269869
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. A polymorphism in plasma platelet-activating factor acetylhydrolase is involved in resistance to immunoglobulin treatment in Kawasaki disease.
    Minami T, Suzuki H, Takeuchi T, Uemura S, Sugatani J, Yoshikawa N.
    J Pediatr; 2005 Jul 27; 147(1):78-83. PubMed ID: 16027700
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.